Next Article in Journal
Health and Lifestyle of Patients with Mesothelioma: Protocol for the Help-Meso Study
Previous Article in Journal
Epidemiological Characteristics of COVID-19 Inpatient Deaths during the First and Second Waves in Limpopo Province, South Africa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoR
Volume 2
Issue 3
10.3390/jor2030010
Review Report
jor-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Use of Mepolizumab in Children and Adolescents with Asthma in the USA

J. Respir. 2022, 2(3), 123-128; https://doi.org/10.3390/jor2030010
by Jaclyn Davis 1, Pamela M. McMahon 2, Emily Welch 2, Cheryl McMahill-Walraven 3, Aziza Jamal-Allial 4, Tancy Zhang 2, Christine Draper 2, Anne Marie Kline 3, Leslie Koerner 4, Jeffrey S. Brown 2, Melissa Van Dyke 5 and Ann Chen Wu 1,2,*
Reviewer 1:
Antonio Molino
Reviewer 2:
Dominika Zając
J. Respir. 2022, 2(3), 123-128; https://doi.org/10.3390/jor2030010
Submission received: 25 May 2022 / Revised: 12 July 2022 / Accepted: 13 July 2022 / Published: 19 July 2022

Round 1

Reviewer 1 Report

The article is clear and well written. It provides an interesting insight of the usage of Mepolizumab on pediatric patients with severe asthma in the US. Maybe it would have been interesting to put up a comparison between European paediatric patients, so as to investigate if the findings are shared with other countries. 

Author Response

Thank you for this comment. Unfortunately we are limited to US claims data and are not positioned to make a comparison to European patients.

Reviewer 2 Report

The paper „The use of mepolizumab in children and adolescents with asthma in the US” by Davis et al. shows how this treatment option is used in a group of patients in the US. As said in the abstract, patients receiving mepolizumab did not have a similar history of previous treatment and that there is no evidence for a profit in the use of this medication.

In the introduction, the authors state that it is not known in which patients biologics might be most effective. In fact, please have a look on https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606967/ and consider to discuss this issue in the discussion.

In the results the authors show that there were no significant changes in the use of other medications and number of asthma exacerbations before and after treatment even if the main goal of the use of biologics is alleviation of asthma symptoms, decrease of use of medications and improved quality of life. What is the reason for such an observation? Where the real reasons or results missing because of the character of the data (from insurance sources)? The authors mention that the main reason for unsuccessful use of the medication are prescriptions in non-severe asthma. Why could be the reason for that? The belief that “new” medications are “better” than the “old” ones or that “biologic” means “more natural” or “safer”?

Why did the authors include into the study subjects with asthma/COPD overlap syndrome and eosinophilic granulomatosis with polyangiitis as these diseases are rather rare in children? Could the authors comment on this?

Please check formatting in the entire document

Author Response

Please see attachment

Author Response File: Author Response.pdf

Back to TopTop